Treatment with bezafibrate to lower cholesterol curbs the incidence and delays the onset of type 2 diabetes in obese individuals, doctors in Israel report.In comments to Reuters Health, study leader Dr. Alexander Tenenbaum from Chaim Sheba Medical Center in Tel-Hashomer noted that obesity has reached “epidemic dimensions worldwide” and is clearly associated with type 2 diabetes and metabolic syndrome -- a cluster of conditions including high blood pressure, high cholesterol and diabetes.
